Novel non-classical C9-methyl-5-substituted-2,4-diaminopyrrolo[2,3- d]pyrimidines as potential inhibitors of dihydrofolate reductase and as anti-opportunistic agents

Abstract

Six novel C9-methyl-5-substituted-2,4-diaminopyrrolo[2,3- d]pyrimidines 18– 23 were synthesized as potential inhibitors of dihydrofolate reductase (DHFR) and as anti-opportunistic agents. These compounds represent the only examples of 9-methyl substitution in the carbon–carbon bridge of 2,4-diaminopyrrolo[2,3- d]pyrimidines. The analogs 18– 23 were synthesized in a concise eight-step procedure starting from the appropriate commercially available aromatic methyl ketones. The key step involved a Michael addition reaction of 2,4,6-triaminopyrimidine to the appropriate 1-nitroalkene, followed by ring closure of the nitro adducts via a Nef reaction. The compounds were evaluated as inhibitors of DHFR from Pneumocystis carinii (pc), Toxoplasma gondii (tg), Mycobacterium avium (ma) and rat liver (rl). The biological result indicated that some of these analogs are potent inhibitors of DHFR and some have selectivity for pathogen DHFR. Compound 23 was a two digit nanomolar inhibitor of tgDHFR with 9.6-fold selectivity for tgDHFR.